ArticleAnnals of pediatric cardiology
Fibroblast growth factor 23 and left ventricular hypertrophy in dialyzed versus nondialyzed children with chronic kidney disease.
Article in Annals of pediatric cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibroblast growth factor 23 (FGF23) is a protein encoded by the FGF23 gene in humans. It belongs to the FGF family, which plays a crucial role in phosphate and Vitamin D metabolism. The primary function of FGF23 appears to be regulating phosphate levels in plasma. Elevated FGF23 levels are consistently linked to left ventricular hypertrophy (LVH) and are a major risk factor for mortality in chronic kidney disease (CKD). We aimed to evaluate the role of FGF23 in assessing the association with LVH in dialyzed versus nondialyzed children with CKD. Patients and Methods: This prospective observational study involved 50 children with CKD divided into two groups: Group I consisted of 34 subjects undergoing regular hemodialysis, whereas Group II included 16 subjects not on hemodialysis. Various tests were done, including serum creatinine, calcium, phosphorus, and FGF23, along with echocardiography. Results: There was a statistically significant increase in FGF23 levels in dialyzed compared to nondialyzed patients. A significant positive correlation was found between serum FGF-23 levels and the duration of dialysis and serum phosphorus. In addition, a positive correlation was observed between FGF23 and left ventricular mass (LVM), LVM index (LVMI), and relative wall thickness (RWT). The area under the curve of FGF23 for identifying LVH was 0.803, with a sensitivity of 85.7% and specificity of 63.9%. Conclusions: Serum FGF-23 levels were significantly increased in dialyzed children compared to nondialyzed children. FGF-23 levels were significantly correlated with serum phosphorus levels, confirming the role of FGF23 in phosphate homeostasis. In addition, there were significant positive correlations between FGF23 levels and LVM, LVMI, and RWT, reinforcing FGF23's role in assessing the association with LVH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.